Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. METHODS: We randomly assigned 792 patients with relapsed multiple myeloma to carfilzomib with lenalidomide and dexamethasone (carfilzomib group) or lenalidomide and dexamethasone alone (control group). The primary end point was progression-free survival. RESULTS: Progression-free survival was significantly improved with carfilzomib (median, 26.3 months, vs. 17.6 months in the control group; hazard ratio for progression or death, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P=0.0001). The median overall survival was not reached in either group at the interim analysis. The Kaplan-Meier 24-month overall survival rates were 73.3% and 65.0% in the carfilzomib and control groups, respectively (hazard ratio for death, 0.79; 95% CI, 0.63 to 0.99; P=0.04). The rates of overall response (partial response or better) were 87.1% and 66.7% in the carfilzomib and control groups, respectively (P<0.001; 31.8% and 9.3% of patients in the respective groups had a complete response or better; 14.1% and 4.3% had a stringent complete response). Adverse events of grade 3 or higher were reported in 83.7% and 80.7% of patients in the carfilzomib and control groups, respectively; 15.3% and 17.7% of patients discontinued treatment owing to adverse events. Patients in the carfilzomib group reported superior health-related quality of life. CONCLUSIONS: In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The KRd regimen has been shown to be effective in a randomized trial, and is a major option for the treatment of relapsed disease (Table 8).67”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [67]
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [27]
In the citing paper
“Pomalidomide is most often used in combination with dexamethasone, either alone or as part of triplet regimens with a variety of other anti-myeloma agents, including bortezomib45, daratumumab46 or elotuzumab47.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [46]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 2×
“The standard-risk group consisted of patients without t(4;14) or t(14;16) and with deletion 17p in less than 60% of plasma cells.”
BackgroundDiscrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citationLenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Self-citationLenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Cited by
Items 601–700 of 1,000
Delivering macrolide antibiotics to heal a broken heart – And other inflammatory conditions
Venditto, V. J., & Feola, D. J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114252 · Cited by 16
Terao, T., Tsushima, T., Miura, D., Ikeda, D., Fukumoto, A., Kuzume, A., Tabata, R., Narita, K., Takeuchi, M., & Matsue, K. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2057485 · Cited by 16
“For KRd and KPd (Cfz, pomalidomide, and dexamethasone), Cfz (a 10-min intravenous [IV] infusion) was administered on days 1, 2, 8, 9, 15, and 16 (starting dose, 20mg/m(2) on days 1 and 2 of cycle 1; target dose, 27mg/m(2) thereafter) of 28-day cycles based on the ASPIRE trial [1].”
MethodDefining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
Goel, U., Charalampous, C. M., Kapoor, P., Binder, M., Buadi, F. K., Dingli, D., Dispenzieri, A. A., Fonder, A. L., Gertz, M. A., Gonsalves, W. I., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00785-y · Cited by 16
Self-citationNew Strategies for the Treatment of Older Myeloma Patients
Larocca, A., Cani, L., Bertuglia, G., Bruno, B., & Bringhen, S. (2023) · Cancers · doi:10.3390/cancers15102693 · Cited by 18
Sobh, M., Michallet, M., Dubois, V., Iacobelli, S., Köster, L., van Biezen, A., Fegueux, N., Tabrizi, R., Finke, J., Cheikh, J. E., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.165399 · Cited by 16
“For the remaining 119 (21%) patients, karyotype abnormalities were reported, with the majority affecting del(13q), and there were 12 high-risk patients with t(4;14) and/or del (17p).”
BackgroundEmerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors
Driscoll, J. J., & Brailey, M. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9698-5 · Cited by 16
Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
Cho, S., Lin, L., Xing, L., Yu, T., Wen, K., Anderson, K. C., & Tai, Y. (2017) · Antibodies · doi:10.3390/antib6040018 · Cited by 16
“The clinical outcome of patients with multiple myeloma has been improved in recent decades due to the development of novel therapeutic agents such as the proteasome inhibitors bortezomib [3], carfilzomib [4,5], and ixazomib [6] or immunomodulatory drugs (IMiDs) including thalidomide [7], lenalidomide [8], and pomalido…”
BackgroundMankinen, P., Vihervaara, V., Torvinen, S., Martikainen, J. A., & Soini, E. J. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1569457 · Cited by 16
Le, G. N., Bones, J., Coyne, M., Bazou, D., Dowling, P., O’Gorman, P., & Larkin, A. (2019) · Molecular Omics · doi:10.1039/c8mo00193f · Cited by 18
Martino, E. A., Conticello, C., Zamagni, E., Pavone, V., Palmieri, S., Musso, M., Tacchetti, P., Mele, A., Catalano, L., Vigna, E., et al. (2022) · Hematological Oncology · doi:10.1002/hon.3035 · Cited by 17
Ailawadhi, S., Mikhael, J. R., LaPlant, B. R., Laumann, K. M., Kumar, S. K., Roy, V., Dingli, D., Bergsagel, P. L., Buadi, F. K., Rajkumar, S. V., et al. (2017) · Leukemia · doi:10.1038/leu.2017.258 · Cited by 16
Self-citationDifferential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020
Sherry, A. D., Hahn, A. W., McCaw, Z. R., Jaoude, J. A., Kouzy, R., Lin, T. A., Minsky, B. D., Fuller, C. D., Meirson, T., Msaouel, P., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.3379 · Cited by 15
Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma
Hoy, S. M. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0428-7 · Cited by 15
“At baseline, patient demographic and disease characteristics were well balanced between the treatment groups [14].”
BackgroundMethodInfluentialSuzuki, K., Ri, M., Chou, T., Sugiura, I., Takezako, N., Sunami, K., Ishida, T., Izumi, T., Ozaki, S., Shumiya, Y., et al. (2017) · Cancer Science · doi:10.1111/cas.13166 · Cited by 15
Management of Multiple Myeloma
Kumar, S. K. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0040 · Cited by 15
Chhabra, S., Szabó, A., Glisch, C., George, G., Narra, R. K., Harrington, A. M., Jerkins, J. H., D’Souza, A., Dhakal, B., Pasquini, M. C., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.02.020 · Cited by 15
Monteith, B. E., Venner, C. P., Reece, D. E., Kew, A. K., Lalancette, M., Garland, J. S., Shepherd, L. E., Pater, J. L., & Hay, A. E. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.04.014 · Cited by 15
Recent advances in the diagnosis and management of amyloid cardiomyopathy
Nijst, P., & Tang, W. H. W. (2021) · Faculty Reviews · doi:10.12703/r/10-31 · Cited by 17
Overcoming drug resistance by targeting protein homeostasis in multiple myeloma
Moscvin, M., Ho, M., & Bianchi, G. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.93 · Cited by 17
Onda, Y., Kanda, J., Kaneko, H., Shimura, Y., Fuchida, S., Nakaya, A., Itou, T., Yamamura, R., Tanaka, H., Shibayama, H., et al. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221104584 · Cited by 15
Georgoulis, V., Haidich, A., Bougioukas, K. I., & Hatzimichael, E. C. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103842 · Cited by 15
Practical Considerations in Managing Relapsed Multiple Myeloma
Agarwal, A., Chow, E., Bhutani, M., Voorhees, P. M., Friend, R. N., & Usmani, S. Z. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.11.010 · Cited by 15
Suzuki, K., Handa, H., Chou, T., Ishizawa, K., Takubo, T., & Kase, Y. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2149-1 · Cited by 15
Which therapies will move to the front line for multiple myeloma?
Cejalvo, M. J., & de la Rubia, J. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1317589 · Cited by 19
Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma
Baljević, M., & Orlowski, R. Z. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1621839 · Cited by 16
“Several advancements and insights regarding PIs have materialized over the last decade: (1) arrival of the first oral PI IXZ which boasts a more convenient route of administration and an improved toxicity profile, resulting in improved quality of life and patient compliance; (2) relative lack of PN with CFZ and IXZ wh…”
Dimopoulos, M. A., Moreau, P., Iida, S., Huang, S., Takezako, N., Chng, W. J., Zahlten‐Kumeli, A., Sersch, M. A., Li, J., Huang, M., et al. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02704-z · Cited by 16
Self-citationPawarode, A., Mineishi, S., Reddy, P. R., Braun, T., Khaled, Y. A., Choi, S. W., Magenau, J. M., Harris, A. C., Connelly, J. A., Kitko, C. L., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.07.021 · Cited by 16
Beling, A., & Kespohl, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02620 · Cited by 17
Kubicki, T., Bednarek, K., Kostrzewska‐Poczekaj, M., Łuczak, M., Lewandowski, K., Gil, L., Jarmuż‐Szymczak, M., & Dytfeld, D. (2022) · PubMed · Cited by 14
Handa, H., Ishida, T., Ozaki, S., Mori, A., Kato, K., & Iida, S. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283931 · Cited by 16
“…drugs those were approved after 2015, particularly in relapsed/refractory MM. Recent clinical studies and meta-analyses reported that triple therapy including newly approved drugs (Carfilzomib, Ixazomib, Elotuzumab, and Daratumumab) are associated with superior efficacy versus dual therapy [22–31].”
BackgroundPuertas, B., González‐Calle, V., Sureda, A. M., Moreno, M. J., Oriol, A., González, E., Rosiñol, L., López‐Pardo, J., Escalante, F., Martínez‐López, J., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282490 · Cited by 15
“Patients treated with KCd developed AE, resulting in earlier discontinuation than in those treated with Kd, after a median of five (1-26) versus 17 cycles (10-20) cycles.”
BackgroundSelf-citationJung, S., Koh, Y., Kim, M. K., Kim, J. S., Moon, J., Min, C., Yoon, D. H., Yoon, S. S., Lee, J., Hong, C. M., et al. (2025) · Blood Research · doi:10.1007/s44313-025-00055-9 · Cited by 15
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies
Larsen, J. T., & Kumar, S. K. (2015) · Rare Cancers and Therapy · doi:10.1007/s40487-015-0009-4 · Cited by 14
Faiman, B. M., Doss, D. S., Colson, K., Mangan, P. A., King, T., Tariman, J. D., & and Board (2017) · Clinical journal of oncology nursing · doi:10.1188/17.cjon.s5.19-36 · Cited by 15
Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma
Hájek, R., Delforge, M., Raab, M. S., Schoen, P., DeCosta, L., Špıčka, I., Radocha, J., Pour, L., Gonzalez‐McQuire, S., & Bouwmeester, W. (2019) · British Journal of Haematology · doi:10.1111/bjh.16105 · Cited by 14
Self-citationRahman, M. R., Ball, S., Paz, P., Elmassry, M., Vutthikraivit, W., Bandyopadhyay, D., Lavie, C. J., & Fonarow, G. C. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.07.006 · Cited by 15
Larocca, A., Leleu, X. P., Touzeau, C., Bladé, J., Paner, A., Mateos, M., Cavo, M., Maisel, C., Alegre, A. M., Oriol, A., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17887 · Cited by 15
Self-citationStratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM
Jeryczynski, G., Bolomsky, A., Agis, H., & Krauth, M. (2021) · Cancers · doi:10.3390/cancers13235886 · Cited by 15
Cardiotoxicity of Chemotherapeutic Drugs: An Update and Future Perspectives.
Bannister, C., Cannata, A. N., Bromage, D. I., & McDonagh, T. A. (2022) · PubMed · doi:10.1097/fjc.0000000000001226 · Cited by 11
Gaballa, M., Ma, J., Rauf, M., Bassett, R. L., Pasvolsky, O., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N. Y., Ramdial, J., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01697-4 · Cited by 14
“Data from the ASPIRE trial showed superior progression-free survival (PFS) with KRD, compared to RD, making it one of the more commonly used salvage regimens [9].”
MethodCardiotoxicity of anti-cancer drugs: cellular mechanisms and clinical implications
Kwok, C., & Nolan, M. T. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1150569 · Cited by 15
A general model for the estimation of societal costs of lost production and informal care in Italy
Pradelli, L., & Ghetti, G. (2017) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v18i1.1278 · Cited by 15
Tzogani, K., Jiménez, J. C., Garcia, I., Sancho-López, A., Martin, M., Moreau, A., Démolis, P., Salmonson, T., Bergh, J. C. S., Laane, E., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0184 · Cited by 14
“CLINICAL EFFICACY The pivotal efficacy study was PX-171-009 (ASPIRE), a randomized, multicenter, phase III study to compare the efficacy and safety of CRd versus Rd in patients with relapsedMM [11].”
MethodSelf-citationRichardson, P. G. G., Holstein, S. A., Schlossman, R. L., Anderson, K. C., Attal, M., & McCarthy, P. L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1409207 · Cited by 14
Teng, Z., Gupta, N., Hua, Z., Liu, G., Samnotra, V., Venkatakrishnan, K., & Labotka, R. (2017) · Clinical and Translational Science · doi:10.1111/cts.12524 · Cited by 15
Chaudhry, M., Steiner, R. E., Claussen, C. M., Patel, K. K., Lee, H. C., Weber, D., Thomas, S. K., Feng, C., Amini, B., Orlowski, R. Z., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1508668 · Cited by 15
Lee, M. J., Miller, Z. C., Park, J. E., Bhattarai, D., Lee, W., & Kim, K. B. (2019) · Scientific Reports · doi:10.1038/s41598-019-40635-1 · Cited by 14
Late Presentation of Carfilzomib Associated Thrombotic Microangiopathy
Haddadin, M., Al-Sadawi, M., Madanat, S., Tam, E. L., Taiwo, E. O., Luhrs, C. A., & McFarlane, S. I. (2019) · American Journal of Medical Case Reports · doi:10.12691/ajmcr-7-10-5 · Cited by 14
New proteasome inhibitors in the management of multiple myeloma
Семочкин, С. В. (2019) · Oncohematology · doi:10.17650/1818-8346-2019-14-2-29-40 · Cited by 16
Parisi, M. S., Leotta, S., Romano, A., Fabro, V. D., Martino, E. A., Calafiore, V., Giubbolini, R., Markovic, U., Leotta, V., Giorgio, M. A. D., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101695 · Cited by 14
“In this scenario, lenalidomide represented the backbone to combine with novel drugs, such as carfilzomib in the ASPIRE trial [2], daratumumab in the POLLUX trial [3], elotuzumab in ELOQUENT study [4], or ixazomib in the TOURMALINE trial [5].”
BackgroundLee, J. H., Park, Y., Kang, K., Lee, J., Lee, H. S., Eom, H., Do, Y. R., Kim, J. S., Yoon, S., Shin, D., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04407-0 · Cited by 14
“Italy Japan ASPIRE [13] [14] [15] [16] [9] [2]”
BackgroundMethodResultInfluentialCarfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells
Lee, M. S., Lim, S. H., Yu, A.-R., Hwang, C. Y., Kang, I., & Yeo, E. (2021) · Biology · doi:10.3390/biology10020153 · Cited by 15
“Carfilzomib (CFZ, also known as PR-171, Kyprolis®) is one of the second generation proteasome inhibitors with improved efficacy and minimal off-target adverse effects, being approved by the FDA and utilized for the treatment of relapsed and refractory MM as a single agent [39–41] or in combination with other drugs [33…”
BackgroundWhen and How to Treat Relapsed Multiple Myeloma
Nathwani, N., Bertamini, L., Banerjee, R. K., Gay, F., Shah, N. D., & Krishnan, A. Y. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320129 · Cited by 14
Concise review ‐ Treatment of multiple myeloma in the very elderly: How do novel agents fit in?
Kint, N., & Delforge, M. (2016) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2016.08.001 · Cited by 15
Lath, D., Buckle, C., Evans, H., Fisher, M., Down, J. M., Lawson, M. A., & Chantry, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199517 · Cited by 15
Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline
Hicks, L. K., Messersmith, H. J., Hadidi, S. S. A. A., Banerjee, R. K., Derman, B. A., Kumar, S. K., Wildes, T. M., Bal, S., Bhella, S., Chmielewski, C., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02587 · Cited by 17
Xu, F., Li, Z., Guan, H., & Ma, J. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02319-w · Cited by 13
Predicting progression events in multiple myeloma from routine blood work
Ferle, M., Grieb, N., Kreuz, M., Ader, J., Goldschmidt, H., Mai, E. K., Bertsch, U., Platzbecker, U., Neumuth, T., Reiche, K., et al. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01636-9 · Cited by 14
“To forecast the blood work at a specific time point, the time series comprising all previous observations leading up to the one in question were used as input for our model.”
Tang, Y., Chen, C., Duan, H., Ma, B., & Liu, P. (2016) · European Radiology · doi:10.1007/s00330-016-4223-8 · Cited by 13
Multiple Liver Nodules Mimicking Metastatic Disease as Initial Presentation of Multiple Myeloma
Tiu, A. C., Potdar, R. R., Arguello-Guerra, V., & Morginstin, M. S. (2018) · Case Reports in Hematology · doi:10.1155/2018/7954816 · Cited by 13
Maintenance and continuous therapy for multiple myeloma
Richardson, P. G. G., Laubach, J. P., Gandolfi, S., Facon, T. T. F., Weisel, K. C., & O’Gorman, P. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1490181 · Cited by 13
“Indeed, the addition of the newer agents ixazomib, carfilzomib, daratumumab, and elotuzumab to Rd has improved PFS versus Rd alone [63,72,77,80].”
BackgroundNetwork meta‐analysis of first‐line treatments in transplant‐ineligible multiple myeloma patients
Gil‐Sierra, M. D., Gimeno‐Ballester, V., Fenix-Caballero, S., & Rey, E. J. A. D. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13407 · Cited by 13
Cope, S. F., Toor, K., Popoff, E., Fonseca, R., Landgren, O., Mateos, M., Weisel, K. C., & Jansen, J. P. (2020) · Value in Health · doi:10.1016/j.jval.2019.11.003 · Cited by 13
Self-citationOld and new generation proteasome inhibitors in multiple myeloma
Montefusco, V., Mussetti, A., Salas, M. Q., Martinelli, G., & Cerchione, C. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04148-8 · Cited by 13
Nonselective proteasome inhibitors in multiple myeloma and future perspectives
Gavriatopoulou, M., Malandrakis, P., Ntanasis‐Stathopoulos, I., & Dimopoulos, M. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1999411 · Cited by 14
“doublet combination of lenalidomide and dexamethasone [69].”
BackgroundSelf-citationŠtork, M., Špıčka, I., Radocha, J., Minařík, J., Jelínek, T., Jungová, A., Pavlíček, P., Pospíšilová, L., Sedlák, F., Štraub, J., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05188-4 · Cited by 13
“Results favoring the less pretreated patients were also shown in other triplet regimens, combining IMIDs and PI, like a pomalidomide-bortezomib-dexamethasone [26], or carfilzomib-lenalidomide-dexamethasone [27, 28].”
ResultSelf-citationFang, J., & Zhou, F. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05444-7 · Cited by 13
Ou, Y. C., Doshi, S., Nguyen, A. H., Jonsson, F., Aggarwal, S. K., Rajangam, K. L., Dimopoulos, M. A., Stewart, A. K., Badros, A. Z., Papadopoulos, K. P., et al. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.850 · Cited by 13
Self-citationDjatche, L. M., Goble, J. A., Chun, G., & Varga, Š. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.1.39 · Cited by 13
Determining treatment intensity in elderly patients with multiple myeloma
Salvini, M., D’Agostino, M., Bonello, F., Boccadoro, M., & Bringhen, S. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1496823 · Cited by 13
A U.S. Cost Analysis of Triplet Regimens for Patients with Previously Treated Multiple Myeloma
Hollmann, S., Moldaver, D., Goyert, N., Grima, D. T., & Maiese, E. M. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.4.449 · Cited by 14
Biran, N., Siegel, D. S. D., Berdeja, J. G., Raje, N. S., Cornell, R. F., Alsina, M., Kovacsovics, T. J., Fang, B., Kimball, A. S., & Landgren, O. (2019) · American Journal of Hematology · doi:10.1002/ajh.25498 · Cited by 13
“0045) in patients with RRMM.(9,10) To improve convenience and lessen the burden on patients and the healthcare system, a less-frequent once-weekly carfilzomib dosing schedule has been investigated.”
BackgroundMethodInfluentialSelf-citationMoving Toward Continuous Therapy in Multiple Myeloma
Bonello, F., Cetani, G., Bertamini, L., Gay, F., & Larocca, A. (2019) · Clinical Hematology International · doi:10.2991/chi.d.191101.001 · Cited by 13
“The toxicity profile was similar in both arms, with the exception of a higher incidence of cardiovascular AEs (hypertension 14% vs 7%), diarrhea (42% vs 34%) and fever (29% vs 21%) in the KRd group [9].”
Agbana, P., Lee, M. J., Rychahou, P. G., Kim, K., & Bae, Y. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-02922-9 · Cited by 13
Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies
Böttcher, S. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9151-8_8 · Cited by 13
Management of fibroids in perimenopausal women
Giannubilo, S. R., Ciavattini, A., Petraglia, F., Castellucci, M., & Ciarmela, P. (2015) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000219 · Cited by 13
Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma
Noonan, K. A., & Colson, K. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.05.005 · Cited by 14
Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma
Offidani, M., Boccadoro, M., Raimondo, F. D., Petrucci, M. T., Tosi, P., & Cavo, M. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00507-x · Cited by 14
MicroRNA-532 exerts oncogenic functions in t(4;14) multiple myeloma by targeting CAMK2N1
Xu, K., Hu, X., Sun, L., Liang, Q., Ouyang, G., Zhang, Y., Mu, Q., & Yan, X. (2019) · Human Cell · doi:10.1007/s13577-019-00276-y · Cited by 13
Lessons Learned from Proteasome Inhibitors, the Paradigm for Targeting Protein Homeostasis in Cancer
Kambhampati, S., & Wiita, A. P. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-40204-4_10 · Cited by 13
Dimopoulos, M. A., Coriu, D., Delimpasi, S., Špıčka, I., Upchurch, T. E., Fang, B., Talpur, R., Faber, E. A., Beksaç, M., & Leleu, X. P. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013101 · Cited by 12
Self-citationRubinstein, S. M., Mohsin, A., Banerjee, R., Ma, W., Mishra, S., Kwok, M., Yang, P. C., Warner, J. L., & Cowan, A. J. (2025) · Frontiers in Digital Health · doi:10.3389/fdgth.2025.1569554 · Cited by 12
Structure-based design of potent and selective inhibitors of the HECT ligase NEDD4
Maspero, E., Cappa, A., Weber, J., Trifiró, P., Amici, R., Bruno, A., Fagà, G., Cecatiello, V., Fattori, R., Leuzzi, B., et al. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01557-4 · Cited by 12
The next generation of novel therapies for the management of relapsed multiple myeloma
Gonsalves, W. I., Milani, P., Derudas, D., & Buadi, F. K. (2016) · Future Oncology · doi:10.2217/fon-2016-0200 · Cited by 12
Montefusco, V., Corso, A., Galli, M., Ardoino, I., Pezzatti, S., Carniti, C., Patriarca, F. F., Gherlinzoni, F., Zambello, R., Sammassimo, S., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.16287 · Cited by 16
Sanchez, L. J., Barley, K. M., Richter, J. R., Franz, J. K., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S. S., Richard, S., & Chari, A. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1804356 · Cited by 12
Kumar, S. K., Fu, A., Niesvizky, R., Jagannath, S., Boccia, R. V., & Raje, N. S. (2021) · Blood Advances · doi:10.1182/bloodadvances.2019001059 · Cited by 12
Self-citationEndoplasmic reticulum stress and proteasome inhibitors in multiple myeloma – a room for improvement
Kubicki, T., Gil, L., & Dytfeld, D. (2021) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15896 · Cited by 13
Zhou, X., Bešše, A., Peter, J., Steinhardt, M., Vogt, C., Nerreter, S., Teufel, E., Stanojkovska, E., Xiao, X., Hornburger, H., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282225 · Cited by 12
“Number of cycles, median (range) 3 (1-10) 3 (1-20) 3 (1-5) 0.”
Next-Generation Therapies for Multiple Myeloma
Meermeier, E. W., Bergsagel, P. L., & Chesi, M. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-014236 · Cited by 12
“…Weber et al. 2007), and proteasome inhibitors (bortezomib, carfilzomib, and ixazomib), starting in 2002 (Moreau et al. 2016, Richardson et al. 2003, Stewart et al. 2015), revolutionized the treatment of MM and was associated with quadrupling the annual rate of improvement in 5-year survival from…”
BackgroundYoshida, T., Ri, M., Kanamori, T., Aoki, S., Ashour, R., Kinoshita, S., Narita, T., Totani, H., Masaki, A., Ito, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24160 · Cited by 14
“In addition, Cfz was shown to have a clinical benefit in the treatment of relapsed and refractory (RR) MM cases when combined with lenalidomide plus dexamethasone treatment [4].”
BackgroundKorean Multiple Myeloma 151 Investigators, Shin, J., Lee, J., Kım, K., Min, C., Lee, J., Suh, C., Kim, J. S., Lee, Y. J., Yoon, S., et al. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2540-1 · Cited by 12
Weisel, K. C., Ludwig, H., Rieth, A., Lebioda, A., & Goldschmidt, H. (2019) · Quality of Life Research · doi:10.1007/s11136-019-02307-5 · Cited by 12
“Similarly, in ASPIRE, only 18 cycles of carfilzomib, lenalidomide, and dexamethasone were permitted, followed by lenalidomide plus dexamethasone [23, 24, 28, 29].”
BackgroundMethodResultInfluentialSelf-citationKocoglu, M. H., & Badros, A. Z. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1756258 · Cited by 13
“Pursuant to this, in 2015, indication was expanded based on the results of the ASPIRE study that investigated the role of twice-a-week carfilzomib addition to lenalidomide and paved the way for combination therapies [26].”
BackgroundWongsaengsak, S., Kopel, J. J., Behera, T. R., Chakraborty, R., & Ball, S. (2020) · British Journal of Haematology · doi:10.1111/bjh.16735 · Cited by 12
Maruyama, D., Iida, S., Ogawa, G., Fukuhara, N., Seo, S., Miyazaki, K., Yoshimitsu, M., Kuroda, J., Tsukamoto, N., Tsujimura, H., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16878 · Cited by 12
CD38 targeted treatment for multiple myeloma
Jelínek, T., Mihályová, J., & Hájek, R. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.131 · Cited by 13
Self-citationKhamis, M. Y., Wu, H.-P., Ma, Q., Li, Y., Ma, L., Zhang, X., & Liu, H. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104754 · Cited by 15
Terpos, E., Stamatelopoulos, K. S., Makris, N., Georgiopoulos, G. A., Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Laina, A., Eleutherakis‐Papaiakovou, E., Fotiou, D., Kanellias, N., et al. (2021) · Cancers · doi:10.3390/cancers13205057 · Cited by 13
Self-citationNext-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches
Szalat, R. E., & Munshi, N. C. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159017 · Cited by 12
Metadata
- Authors
- Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A. J., San-Miguel, J. F., Ludwig, H., Wang, M., Maisnar, V., Minarik, J., Bensinger, W. I., Mateos, M.-V., Ben-Yehuda, D., Kukreti, V., Zojwalla, N., Tonda, M. E., Yang, X., Xing, B., Moreau, P., & Palumbo, A.
- Affiliations
- Mayo Clinic in Arizona (US)
- Mayo Clinic (US)
- Alexandra Hospital (GR)
- Semmelweis University (HU)
- Josep Carreras Leukaemia Research Institute (ES)
- University of Ostrava (CZ)
- Hospital Clínic de Barcelona (ES)
- Hackensack University Medical Center (US)
- Queen Giovanna Hospital (BG)
- University Multipurpose Hospital for Active Treatment "Sveti Georgi" (BG)
- Somogy Megyei Kaposi Mór Oktató Kórház (HU)
- The First Republican Clinical Hospital of the Ministry of Health of the Udmurt Republic (RU)
- University of Chicago (US)
- Wilhelminen Hospital (AT)
- The University of Texas MD Anderson Cancer Center (US)
- Charles University (CZ)
- Fred Hutch Cancer Center (US)
- Princess Margaret Cancer Centre (CA)
- Université de Nantes (FR)
- University of Turin (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-01-08
- Volume
- 372
- Issue
- 2
- Pages
- 142-152
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1985864219
- Semantic Scholar
- 6c229c6500f2d44efe03b42aea66351261666d13
- Cited by
- 1,332
- References
- 33
- Citations by year
- 2026: 36 · 2025: 62 · 2024: 63 · 2023: 79 · 2022: 112 · 2021: 137 · 2020: 149 · 2019: 131 · 2018: 166 · 2017: 168 · 2016: 148 · 2015: 77
- FWCI
- 93.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- carfilzomib, lenalidomide, dexamethasone, relapsed multiple myeloma, proteasome inhibitors, progression-free survival, overall survival, adverse events, health-related quality of life, combination therapy, treatment response, interim analysis, treatment discontinuation, stringent complete response, partial response, complete response, overall response rate
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Oligopeptides, Recurrence, Thalidomide, Kaplan-Meier Estimate, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.